Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Net Income (2022 - 2025)

Historic Net Income for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$18.4 million.

  • BioXcel Therapeutics' Net Income rose 55.23% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.2 million, marking a year-over-year increase of 2477.86%. This contributed to the annual value of -$79.8 million for FY2024, which is 5554.56% up from last year.
  • Latest data reveals that BioXcel Therapeutics reported Net Income of -$18.4 million as of Q3 2025, which was up 55.23% from -$19.8 million recorded in Q2 2025.
  • BioXcel Therapeutics' Net Income's 5-year high stood at -$13.8 million during Q1 2025, with a 5-year trough of -$54.3 million in Q4 2022.
  • Over the past 4 years, BioXcel Therapeutics' median Net Income value was -$26.8 million (recorded in 2024), while the average stood at -$31.8 million.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 6697.38% in 2023, then soared by 6341.79% in 2024.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Net Income stood at -$54.3 million in 2022, then surged by 58.84% to -$22.4 million in 2023, then skyrocketed by 36.7% to -$14.2 million in 2024, then decreased by 29.72% to -$18.4 million in 2025.
  • Its last three reported values are -$18.4 million in Q3 2025, -$19.8 million for Q2 2025, and -$13.8 million during Q1 2025.